home / stock / pte / pte news


PTE News and Press, PolarityTE Inc. From 01/18/22

Stock Information

Company Name: PolarityTE Inc.
Stock Symbol: PTE
Market: NASDAQ
Website: polarityte.com

Menu

PTE PTE Quote PTE Short PTE News PTE Articles PTE Message Board
Get PTE Alerts

News, Short Squeeze, Breakout and More Instantly...

PTE - Stock Market News for Today, January 18th, 2022

Trading Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here and in full effect, there is a lot for investors to keep track of. While volatility remains extremely high right now, having a consistent understanding of the lat...

PTE - PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication PR Newswire SALT LAKE CITY , Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company develo...

PTE - 8 Top Penny Stocks to Watch Today: EVGRF, PTE, BLCT, GNPX, AFI, CELZ, AUVI, WAVE

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the top penny stocks to watch today as several names in the space see major movement. Source: John Brueske/Shutterstock.com Penny stocks are a favorite among day and retail traders looking t...

PTE - PolarityTE submits complete response to FDA's clinical hold for SkinTE application

PolarityTE (NASDAQ:PTE) has submitted its complete response to the FDA's clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE with a proposed indication for chronic cutaneous ulcers. Shares up 5% premarket at $0.41. As previously disc...

PTE - PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application PR Newswire SALT LAKE CITY , Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company ...

PTE - PolarityTE, Inc.'s (PTE) CEO Richard Hague on Q3 2021 Results - Earnings Call Transcript

PolarityTE, Inc. (PTE) Q3 2021 Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants Cameron Hoyler - General Counsel Richard Hague - President and CEO Jake Patterson - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Presentation O...

PTE - PolarityTE EPS beats by $0.03, beats on revenue

PolarityTE (NASDAQ:PTE): Q3 Non-GAAP EPS of -$0.09 beats by $0.03; GAAP EPS of -$0.01 beats by $0.11. Revenue of $1.12M (-66.5% Y/Y) beats by $0.31M. Press Release For further details see: PolarityTE EPS beats by $0.03, beats on revenue

PTE - PolarityTE Reports Third Quarter Financial Results and Provides Business Update

PolarityTE Reports Third Quarter Financial Results and Provides Business Update PolarityTE to host conference call and webcast today, November 10, 2021, at 8:30 a.m. ET PR Newswire SALT LAKE CITY , Nov. 10, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: P...

PTE - PolarityTE Q3 2021 Earnings Preview

PolarityTE (NASDAQ:PTE) is scheduled to announce Q3 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.12 (+33.3% Y/Y) and the consensus Revenue Estimate is $0.81M (-75.7% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision ...

PTE - Notable earnings before Wednesday's open

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

Previous 10 Next 10